+91 780-304-0404

Ozempic Market

Ozempic Market Size, Share & Trends Analysis Report by Indication (Type-2 Diabetes, Obesity / Weight Management, Cardiovascular-Risk-Reduction (anticipated), and Other Emerging Uses), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online / Mail-Order Pharmacies, and Tele-health Platforms), Forecast Period (2025-2035)

Published: Feb 2026 | Report Code: OMR2028928 | Category : Pharmaceuticals | Delivery Format: /

Industry Overview

Ozempic market was valued at $24.7 billion in 2024 and is projected to reach $66.5 billion by 2035, growing at a CAGR of 9.4% during the forecast period (2025-2035). The demand for Ozempic is driven by its proven clinical effectiveness in improving glycemic control. The rising incidence of type-2 diabetes globally is encouraging wider adoption of semaglutide-based therapies. Pharmaceutical companies are actively increasing production capacity to meet the growing patient pool. In addition, physicians are increasingly prescribing Ozempic as a preferred treatment owing to favorable safety and efficacy data. Expanding insurance coverage and reimbursement support are fueling its accessibility across key markets.

  • In 2023, Novo Nordisk reported combined global sales of approximately $21.1 billion for Ozempic, Rybelsus, and Wegovy, accounting for nearly two-thirds of the company’s total revenue and representing an 89% increase compared with the previous year. More than 70% of semaglutide sales were generated in the US market.

ozempic market dynamics

Market Dynamics

Rising Adoption in Type-2 Diabetes Management

The global Ozempic market is experiencing a strong uptake as healthcare professionals increasingly endorse it in healthcare settings for patients with type 2 diabetes. Novo Nordisk, the manufacturer of Ozempic, continues to expand its global footprint through thoughtful investments in enhancing supply and awareness of patients as to the potential long-term benefits of treatment with semaglutide, further strengthening Ozempic among diabetes treatment options.

Expanding Role in Obesity Treatment

Beyond type-2 diabetes treatment, Ozempic is gaining traction in the obesity management space, motivated by positive clinical performance. Eli Lilly, another manufacturer with GLP-1 therapy options, is introducing active competition into the obesity management space while providing more treatment options within the space. Engaging a range of compound manufacturers is challenging innovation and options for patients globally.

ozempic market porters five forces analysis

Market Segmentation

  • Based on the indication, the market is segmented into type-2 diabetes, obesity/weight management, cardiovascular-risk-reduction (anticipated), and other emerging uses.
  • Based on the distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, online / mail-order pharmacies, and tele-health platforms.

Type-2 Diabetes Segment to Lead the Market with the Largest Share

The prevalence of type-2 diabetes is steadily increasing, creating consistent demand for advanced therapeutic options. Novo Nordisk, the developer of Ozempic, has positioned semaglutide as a leading treatment with demonstrated clinical outcomes. Physicians are prioritizing therapies that improve long-term glycemic control with fewer side effects. This has supported the rapid uptake of Ozempic across hospital and outpatient settings. Growing clinical guidelines are recommending GLP-1 receptor agonists as a preferred option.

Retail Pharmacies: A Key Segment in Market Growth

Retail pharmacies are playing an important role in the distribution of Ozempic, improving availability to patients. Chains such as CVS Health in the US are expanding access by ensuring consistent stocking of semaglutide-based therapies. This retail channel enhances patient engagement with actual pharmacist-led- led counseling, convenience, and better accessibility of care. The increasing use of pharmacies is clearly demonstrated through walk-in volume. Growing demand from walk-in patients highlights their importance in therapy adoption.  

Regional Outlook

The global ozempic market is further divided by geography, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).

Increasing Demand for Advanced Diabetes Management Solutions in Europe

Ozempic is experiencing a surge in popularity in Europe, driven by the increasing desire of governments to better care for people with diabetes. The UK saw organizations like Boots expand the availability of semaglutide as a treatment through pharmacy treatment services. Coordinated healthcare efforts across the EU are allowing for broader distribution of GLP-1 receptor agonists. In Germany and France, the leading markets, physicians are confidently prescribing Ozempic after the publication of clinical guidelines. Patient trust in Novo Nordisk’s product portfolio further reinforces its uptake.

North America Region Dominates the Market with a Major Share

The North American market remains a key revenue contributor for Ozempic owing to a high diabetes prevalence. Novo Nordisk has set up effective distribution channels throughout the US to ensure product access. Reimbursement policies support quicker adoption of prescriptions among a varied patient population. Healthcare providers in the US are nimble at adopting new therapies based on guidelines. These patient awareness campaigns have been valuable in improving treatment initiation and adherence.

Market Players Outlook

The major companies operating in the global ozempic market include Sumitomo Pharma Co., Ltd., Novo Nordisk A/S, GEROPHARM LLC, Biocon Ltd., Eli Lilly and Co., among others. Market players are leveraging partnerships, collaborations, mergers and acquisitions strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments

  • In December 2024, Eli Lilly and Co. announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial. Zepbound (tirzepatide) provided a 47% greater relative weight loss compared to Wegovy (semaglutide). On average, Zepbound led to a superior weight loss of 20.2% compared to 13.7% with Wegovy. At 72 weeks, Zepbound beat Wegovy on both the primary endpoint and all five key secondary endpoints in this trial of adults living with obesity or overweight with at least one weight-related medical problem and without diabetes.
  • In April 2024, Biocon Ltd., an innovation-led global biopharmaceutical company, announced the signing of an exclusive licensing and supply agreement with Biomm S.A., a specialty pharmaceutical company in Brazil, for the commercialization of its vertically integrated drug product, Semaglutide (gOzempic), which is used to improve glycemic control in adults with type 2 diabetes.
  • In October 2023, GEROPHARM relaunched the drug Ozempic in Russia under the brand name Semavic. This product will serve as a replacement for Ozempic, which is no longer available in the Russian market after Novo Nordisk, Denmark, discontinued its shipments earlier this year, despite the drug being classified as a “life-saving” medicinal product. GEROPHARM possesses the required manufacturing facilities and has the capacity to meet the domestic demand for this therapy. Semaglutide-based medicines such as Semavic are considered among the most advanced and promising treatments for type 2 diabetes mellitus.

The Report Covers

  • Market value data analysis of 2024 and forecast to 2035.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global ozempic market. Based on the availability of data, information related to new products and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying ‘who-stands-where’ in the market.
  1. Report Summary
  • Current Industry Analysis and Growth Potential Outlook
  • Global Ozempic Market Sales Analysis – Indication| Distribution Channel ($ Million)
  • Ozempic Market Sales Performance of Top Countries
    • Research Methodology
  • Primary Research Approach
  • Secondary Research Approach
    • Market Snapshot
  1. Market Overview and Insights
    • Scope of the Study
    • Analyst Insight & Current Market Trends
      • Key Ozempic Market Trends
      • Market Recommendations
    • Porter's Five Forces Analysis for the Ozempic Market
      • Competitive Rivalry
      • Threat of New Entrants
      • Bargaining Power of Suppliers
      • Bargaining Power of Buyers
      • Threat of Substitutes
  1. Market Determinants
    • Market Drivers
      • Drivers For Global Ozempic Market: Impact Analysis
    • Market Pain Points and Challenges
      • Restraints For Global Ozempic Market: Impact Analysis
    • Market Opportunities
      • Opportunities For Global Ozempic Market: Impact Analysis
  1. Competitive Landscape
    • Competitive Dashboard – Ozempic Market Revenue and Share by Manufacturers
  • Ozempic Product Comparison Analysis
  • Top Market Player Ranking Matrix
    • Key Company Analysis
      • Biocon Ltd.
        • Overview
        • Product Portfolio
        • Financial Analysis (Subject to Data Availability)
        • SWOT Analysis
        • Business Strategy
      • Eli Lilly and Co.
        • Overview
        • Product Portfolio
        • Financial Analysis (Subject to Data Availability)
        • SWOT Analysis
        • Business Strategy
      • GEROPHARM LLC
        • Overview
        • Product Portfolio
        • Financial Analysis (Subject to Data Availability)
        • SWOT Analysis
        • Business Strategy
      • Novo Nordisk A/S
        • Overview
        • Product Portfolio
        • Financial Analysis (Subject to Data Availability)
        • SWOT Analysis
        • Business Strategy
      • Sumitomo Pharma Co., Ltd.
        • Overview
        • Product Portfolio
        • Financial Analysis (Subject to Data Availability)
        • SWOT Analysis
        • Business Strategy
      • Top Winning Strategies by Market Players
        • Merger and Acquisition
        • Product Launch
        • Partnership And Collaboration
  1. Global Ozempic Market Sales Analysis by Indication ($ Million)
    • Type-2 Diabetes
    • Obesity / Weight Management
    • Cardiovascular-Risk-Reduction (anticipated)
    • Other Emerging Uses
  1. Global Ozempic Market Sales Analysis by Distribution Channel ($ Million)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online / Mail-Order Pharmacies
    • Tele-health Platforms
  1. Regional Analysis
    • North American Ozempic Market Sales Analysis – Indication| Distribution Channel | Country ($ Million)
  • Macroeconomic Factors for North America
    • United States
    • Canada
  • European Ozempic Market Sales Analysis – Indication| Distribution Channel | Country ($ Million)
  • Macroeconomic Factors for Europe
    • UK
    • Germany
    • Italy
    • Spain
    • France
    • Russia
    • Rest of Europe
  • Asia-Pacific Ozempic Market Sales Analysis – Indication| Distribution Channel | Country ($ Million)
  • Macroeconomic Factors for Asia-Pacific
    • China
    • Japan
    • South Korea
    • India
    • Australia & New Zealand
    • ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
    • Rest of Asia-Pacific
  • Rest of the World Ozempic Market Sales Analysis – Indication| Distribution Channel | Country ($ Million)
  • Macroeconomic Factors for the Rest of the World
    • Latin America
    • Middle East and Africa

 

  1. Company Profiles

1. Global Ozempic Market Research And Analysis By Indication, 2024–2035 ($ Million)

2. Global Type-2 Ozempic Diabetes Market Research And Analysis By Region, 2024–2035 ($ Million)

3. Global Obesity / Weight Management Ozempic Market Research And Analysis By Region, 2024–2035 ($ Million)

4. Global Cardiovascular-Risk-Reduction (Anticipated) Ozempic Market Research And Analysis By Region, 2024–2035 ($ Million)

5. Global Other Ozempic Indication Market Research And Analysis By Region, 2024–2035 ($ Million)

6. Global Ozempic Market Research And Analysis By Distribution Channel, 2024–2035 ($ Million)

7. Global Ozempic  Via Hospital Pharmacies Market Research And Analysis By Region, 2024–2035 ($ Million)

8. Global Ozempic  Via Retail Pharmacies Market Research And Analysis By Region, 2024–2035 ($ Million)

9. Global Ozempic  Via Online / Mail-Order Pharmacies Market Research And Analysis By Region, 2024–2035 ($ Million)

10. Global Ozempic Via Tele-health Platforms Market Research And Analysis By Region, 2024–2035 ($ Million)

11. Global Ozempic Market Research And Analysis By Region, 2024–2035 ($ Million)

12. North American Ozempic Market Research And Analysis By Country, 2024–2035 ($ Million)

13. North American Ozempic Market Research And Analysis By Indication, 2024–2035 ($ Million)

14. North American Ozempic Market Research And Analysis By Distribution Channel, 2024–2035 ($ Million)

15. European Ozempic Market Research And Analysis By Country, 2024–2035 ($ Million)

16. European Ozempic Market Research And Analysis By Indication, 2024–2035 ($ Million)

17. European Ozempic Market Research And Analysis By Distribution Channel, 2024–2035 ($ Million)

18. Asia-Pacific Ozempic Market Research And Analysis By Country, 2024–2035 ($ Million)

19. Asia-Pacific Ozempic Market Research And Analysis By Indication, 2024–2035 ($ Million)

20. Asia-Pacific Ozempic Market Research And Analysis By Distribution Channel, 2024–2035 ($ Million)

21. Rest Of The World Ozempic Market Research And Analysis By Region, 2024–2035 ($ Million)

22. Rest Of The World Ozempic Market Research And Analysis By Indication, 2024–2035 ($ Million)

23. Rest Of The World Ozempic Market Research And Analysis By Distribution Channel, 2024–2035 ($ Million)

1. Global Ozempic Market Share By Indication, 2024 Vs 2035 (%)

2. Global Type-2 Ozempic Diabetes Market Share By Region, 2024 Vs 2035 (%)

3. Global Obesity / Weight Management Ozempic Market Share By Region, 2024 Vs 2035 (%)

4. Global Cardiovascular-Risk-Reduction (Anticipated) Ozempic Market Share By Region, 2024 Vs 2035 (%)

5. Global Other Ozempic Indication Market Share By Region, 2024 Vs 2035 (%)

6. Global Ozempic Market Share By Distribution Channel, 2024 Vs 2035 (%)

7. Global Ozempic Via Hospital Pharmacies Market Share By Region, 2024 Vs 2035 (%)

8. Global Ozempic Via Retail Pharmacies Market Share By Region, 2024 Vs 2035 (%)

9. Global Ozempic Via Online / Mail-Order Pharmacies Market Share By Region, 2024 Vs 2035 (%)

10. Global Ozempic Via Tele-health Platforms Market Share By Region, 2024 Vs 2035 (%)

11. Global Ozempic Market Share By Region, 2024 Vs 2035 (%)

12. US Ozempic Market Size, 2024–2035 ($ Million)

13. Canada Ozempic Market Size, 2024–2035 ($ Million)

14. UK Ozempic Market Size, 2024–2035 ($ Million)

15. France Ozempic Market Size, 2024–2035 ($ Million)

16. Germany Ozempic Market Size, 2024–2035 ($ Million)

17. Italy Ozempic Market Size, 2024–2035 ($ Million)

18. Spain Ozempic Market Size, 2024–2035 ($ Million)

19. Russia Ozempic Market Size, 2024–2035 ($ Million)

20. Rest Of Europe Ozempic Market Size, 2024–2035 ($ Million)

21. India Ozempic Market Size, 2024–2035 ($ Million)

22. China Ozempic Market Size, 2024–2035 ($ Million)

23. Japan Ozempic Market Size, 2024–2035 ($ Million)

24. South Korea Ozempic Market Size, 2024–2035 ($ Million)

25. Australia And New Zealand Ozempic Market Size, 2024–2035 ($ Million)

26. ASEAN Economies Ozempic Market Size, 2024–2035 ($ Million)

27. Rest Of Asia-Pacific Ozempic Market Size, 2024–2035 ($ Million)

28. Latin America Ozempic Market Size, 2024–2035 ($ Million)

29. Middle East And Africa Ozempic Market Size, 2024–2035 ($ Million)

Choose License Type
    Discount Available
Enterprise Custom
  • Printable version
  • No restriction to number of user within the company

Contact Sales

100%
Secured Payment

Why buy from us?
  • Covers more than 15 major industries, which are further segmented into 90+ sectors
  • 65% of our clients are loyal customers
  • 120+ countries are covered in analysis
  • currently servicing 1000+ customers globally
  • 100+ paid data sources mined to research
  • Our expert team will assist you with all research need and customization
  • Our expert research analyst will resolve your every query before and after purchasing the report
Related Reports

FAQS

The size of the Ozempic market in 2024 is estimated to be around $24.7 billion.

North America holds the largest share in the Ozempic market.

Leading players in the Ozempic market include Sumitomo Pharma Co., Ltd., Novo Nordisk A/S, GEROPHARM LLC, Biocon Ltd., Eli Lilly and Co., among others.

Ozempic market is expected to grow at a CAGR of 9.4% from 2025 to 2035.

The Ozempic market is growing due to rising prevalence of type 2 diabetes, increasing obesity rates, and growing adoption of GLP-1 receptor agonists for weight management.